the rate of its use has increased, along with a concomitant rise in vitamin D testing. 3 Despite that most test results are from patients with normal or deficient levels, the incidence of vitamin D toxicity has also risen. 4 Vitamin D toxicity is poorly understood and not well defined in the literature. 5 Multiple commercial reference laboratories have varying cut-off values for the upper limit of normal for 25-hydroxyvitamin D [25(OH)D] levels. Further, potentially toxic levels of 25(OH)D have been shown to correlate poorly with hypercalcemia and symptomatic presentation. Vitamin D toxicity has been reported in multiple age groups and from multiple causes, including manufacturing errors, errors in milk fortification, incorrect dosing from liquid preparations, and intentional (although with no intent to harm) ingestion of megadoses of vitamin D supplements. [6] [7] [8] [9] [10] Among these causes, the most harmful appears to be sustained ingestion of megadoses (eg 50,000 IU) and incorrect dosing of supplements in children. We performed a medical-record review in patients with elevated 25(OH)D levels during a 16-year period at an academic medical center, in
Materials and Methods
The study was conducted at the University of Iowa Hospitals and Clinics (UIHC), a 734-bed tertiary-/quaternary-care academic medical center located in Iowa City, Iowa. The data in the study were collected as part of a retrospective study approved by the University of Iowa Institutional Review Board (protocol #201612810), covering the time period from January 1, 2000, through December 31, 2016. This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
As described in a previous study coauthored by one of us, Epic Reporting Workbench (RWB) was used to retrieve past laboratory results and medication administration records.
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In the retrospective timeframe, all serum/plasma 25(OH)D levels derived from testing performed for clinical purposes were retrieved from the electronic medical record. We did an additional search using RWB for patients in the retrospective time period with clinical encounter diagnostic codes related to "vitamin D poisoning" (ICD-9: 278.4; ICD-10, E67.3), "vitamin D overdose" or "vitamin D poisoning" (ICD-9: 963.5, E858.1, E962.0, E969, E980.4; ICD-10, T45.2X), and "vitamin D toxicity" (ICD-9: 278.4; ICD-10, T45.2X). Figure 1 ). Based on reported history, 17 patients were taking 50,000-IU tablets, 4 were taking 20,000-IU tablets, 6
were taking 10,000-IU tablets, 11 were taking 5000-IU tablets, and 6 were taking 1000-IU tablets ( Figure 2 ). Also, 7 were taking liquid formulations with varying concentrations. The remaining patients were reportedly taking a combination of multivitamin and "other" supplements ( Table 2) . Eighteen patients had no vitamin D supplementation recorded in their medical record.
A total of 53 patients had concomitant serum/plasma total calcium drawn at the time of 25(OH)D testing. Only 7 of these patients had total calcium levels higher than the upper limit of the reference range (3 of whom were experiencing symptoms). In these 7 patients, total calcium values ranged from 10.8 to 19.8 mg per dL. The median was 13.3 mg per dL, and the mean was 13.8 mg per dL. For the remaining 47 patients, the total calcium concentrations ranged from 7.3 to 10.5 mg per dL (normal range, 8.5 to 10.5 mg/dL), with a median of 9.4 mg per dL. Based on linear regression statistical analysis, the correlation between vitamin D concentrations and total serum/plasma calcium concentrations was weak, with an r 2 value of 0.10 ( Figure 3 ).
Among the patients with elevated 25(OH)D levels greater than 120 ng per mL, only 4 showed symptoms of vitamin D toxicity ( Table 3 ). had a normal total serum/plasma calcium concentration, at 9.6 mg per dL, but had abdominal pain, severe constipation, and nausea. She was taking 50,000 units of vitamin D per day, also in liquid form. Patient 4 was a 70-year-old non-Hispanic white woman with a 25(OH)D concentration of 194 ng per mL. She had an elevated calcium concentration of 11.4 mg per dL and had experienced renal failure, weakness, confusion, low mood, poor balance, and slurred speech. Her vitamin D supplementation reportedly consisted of only a single 1000 IU tablet per day; however, the reported history may be inaccurate.
The 2 patients with the most severe symptoms were pediatric patients receiving liquid vitamin D via "droppers." In both instances, the incorrect dosage was administered due to confusion between the words "dropperful" and "drop." As a result, the patients received an entire dropperful of liquid vitamin D and, on occasion, 2 to 3 entire droppersful, instead of the correct 1 to 3 drops.
The healthcare professionals treating those patients were able to obtain the original bottles of vitamin D and to determine that a dropper contained approximately 50 drops. There were 1000 IU per drop. Thus, patient 1 was receiving 100,000-150,000 IU per day. Also, based on the amount of vitamin D left in the bottle, it was estimated that he had received approximately 1.6 to 1.7 million units during an 8-week period. The parents of the second patient misinterpreted the instructions and also administered 1 dropperful instead of 1 drop. In this case, each drop contained 2000 IU. It was estimated that patient 2 received 3.5 to 5.5 million IU during a 6-month period, based on the amount of supplement left in the bottle.
Although we did not perform a detailed medical record review for patients with 25(OH)D less than 120 ng per mL, we did a search in the electronic medical records for patients with diagnostic codes related to "vitamin D poisoning," "vitamin D overdose," "vitamin D poisoning," or "vitamin D toxicity," to determine whether any hypervitaminosis D cases were missed. The results of this search identified many of the patients with serum/plasma 25(OH) D concentrations greater than 120 ng per mL whose cases were already reviewed in detail and also identified 7 patients assigned these diagnostic codes who did not have serum/ plasma 25(OH)D concentrations exceeding 120 ng per mL. All 7 of these patients had at least a single 25(OH)D concentration greater than 80 ng per mL but none had values exceeding 120 ng per mL. None of these 7 case individuals had any symptoms suggestive of vitamin D toxicity. Further, 6 of the 7 patients had serum/plasma total calcium measurement(s) concurrent with the elevated 25(OH)D levels. For 
Figure 3
Correlation between 25(OH)D levels and serum/plasma calcium concentrations. Linear regression statistics (95% confidence interval in parentheses): slope, 19.1 (3.5-34.7), y intercept, −0.14 (−157.1 to 156.9), r 2 = 0.10. these 6 patients, total calcium concentrations were all within the reference range; the remaining patient did not have total calcium analysis performed.
Discussion
Consistent with the findings of previous studies, 3 Major clinical laboratories have varying cut-off points for excess levels. 13 A previous study 14 reported that a value of 125 ng per mL can be used as an upper limit of normal. In another study, toxicity was not observed until values exceeded 200 ng per mL. However, toxicity was mentioned in 1 patient report of a 25(OH)D serum/plasma concentration of only 80 ng per mL. 12 We did not encounter such outcomes in patients until a 25(OH)D concentration of 194 ng per mL was achieved. Of the remaining patients experiencing symptoms, one had a level higher than 200 ng per mL, whereas the others had levels higher than 400 ng per mL. Further, similar to results reported by Dudenkov et al, 17 we discovered that potentially "toxic" levels of vitamin D did not strongly correlate with hypercalcemia. We limited our detailed medical-record review to cases in which the level of 25(OH)D exceeded 120 ng per mL. It is possible that some patients showed toxicity at lower 25(OH)D levels; however, our results align with those of other studies, such that these events appear to be rare.
The results of previous studies 3, 12, 15 have shown that most cases of potentially toxic 25(OH)D levels occurred due to use of high-dose vitamin D supplementation. Patients taking high-dose concentrations and liquid supplementation were at increased risk for higher 25(OH)D levels. Doses containing 50,000 IU were common in patients with high 25(OH)D levels in our study. This finding highlights the risk of someone overdosing or taking the incorrect amount with such concentrated doses.
We observed a higher rate of adverse outcomes associated with liquid vitamin D formulations. Specifically, we found 2 pediatric overdose cases in which an incorrect amount of supplement was dispensed from a dropper. Instead of receiving a drop of vitamin D, both patients received 1 entire dropperful due to confusion between the terms "drop" and "dropperful." Both misunderstandings resulted in these children receiving hundreds of thousands of IU or more of vitamin D during the course of a few months. Both patients showed symptoms and had elevated calcium levels and required hospital stays and treatment. Other case reports have also reported vitamin D toxicity resulting from liquid formulations. 8, 18, 19 In each case, the infant received droppersful instead of drops. In one case, a dropperful had been the correct dose on a previous formulation; however, the new supplement only required 1 drop. Our experience and the documented case reports highlight the danger associated with liquid formulations and the lack of standardized dosing in this area. Perhaps it is time for standardization of supplement formulation and simplification of administration methods, or other such measures, to enhance safety.
As a result of its retrospective nature, our study has certain limitations. First, the medical record review focused on common, recognizable symptoms of vitamin D toxicity. It is possible that more subtle toxicity was not evident on medical record review.
Second, we did not perform a detailed medical record review on patients who had vitamin D levels less than 120 ng per mL. 
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Conclusion
We report that symptomatic vitamin D toxicity is quite rare. We investigated a large cohort of patients with vitamin D levels characterized as elevated by current guidelines; however, most of these patients did not show untoward effects from the elevated levels. 
